Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes

Abstract

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

“…In total, there are 5 studies indicating that SRSF2 mutation cause higher risk of AML transformation. Meanwhile, the studies by Hong et al and Yan et al did not find any association between SRSF2 and AML transformation (Hong et al, 2015;Yan et al, 2021). Pooled hazard ratio showed that patients with SRSF2 mutation had higher risk of leukemia transformation (HR 2.62; 95% CI: 1.54-4.45; p= .0004).…”

“…However, 4 articles were not in English language, 2 articles were nonhuman studies, 6 articles did not have outcome of AML progression, and 6 articles did not have adequate data for hazard ratio calculation. Thus, we identified 14 articles to be used for this systematic review and meta-analysis (Dicker et al, 2010;Malcovati et al, 2011;Walter et al, 2011;Thol et al, 2012;Wu et al, 2013a;Lin et al, 2014;Hong et al, 2015;Kang et al, 2015;Jung et al, 2016;Tefferi et al, 2017;Xu et al, 2017;Gangat et al, 2018;Lin et al, 2018;Yan et al, 2021).…”

Impact of IPSS-M implementation in real-life clinical practice

“…In recent years, the development of new technologies has led to a great improvement in our knowledge of the genetic landscape in MDS. Multiple studies have investigated the role of somatic mutation in MDS patient outcome (6)(7)(8)(9)(10)(11).…”